Illuminating Glial Dysfunction in Alzheimer’s Disease with Optical Coherence Tomography

利用光学相干断层扫描揭示阿尔茨海默病中的神经胶质功能障碍

基本信息

  • 批准号:
    10571184
  • 负责人:
  • 金额:
    $ 16.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-03-01 至 2028-02-29
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY / ABSTRACT Clearance of amyloid beta (Aβ) is facilitated by glial cells, and impaired Aβ clearance is implicated in the pathogenesis of Alzheimer’s disease (AD). A non-invasive assay of glial function could translate this knowledge into improved health outcomes – leading to the development of new diagnostic tools and/or glia-targeted therapies. Compared to other parts of the central nervous system (CNS), the retina is structurally simple. Within the avascular layers the retina, where the only neuronal elements are photoreceptors, adjacent glia-rich and glia- free layers can inform on glial health. In this project, functional responses to light in those avascular layers of the retina will be monitored with optical coherence tomography (OCT), which is non-invasive and in current widespread clinical use. Responses in the glia-rich and glia-free layers of the retina report on local shifts in water content, which are foundational to glia-mediated waste clearance. For the first Aim of this project, we will compare functional OCT measurements in patients with AD, patients with non-Alzheimer’s dementia, and healthy age- matched adults. We hypothesize that the functional OCT abnormality in AD is disease-specific and is present at early stages of the disease. Positive results would validate a new low-cost, non-invasive, and diagnostically useful marker of AD. The second Aim of this project will use OCT to non-invasively measure retinal glial function in genetic mouse models of disease. Knockout mice lacking the aquaporin 4 protein have impaired glial water and waste clearance. Those mice will be crossed with APP/PS1 mice, a common model of AD based on Aβ overproduction. Functional OCT abnormalities in these mice may be caused by limitations in glial water movement, or by Aβ accumulation, or these features of AD may be synergistic. In vitro OCT of glial cells cultured from those mice will clarify the glial contribution to OCT abnormalities. Positive findings from this Aim would validate OCT as the first clinically-available tool to measure glial function, and provide a direct cell-to-mouse-to- human translational approach for the assessment of glial function in neurodegenerative disease. My career goal is to become an independently-funded physician-scientist studying AD and related dementias. This mentored career development proposal builds upon my clinical experience as a fellowship- trained dementia neurologist, and my research experience in OCT in Alzheimer’s patients as well as (non-OCT) imaging of the rodent retina. The University of California – Davis is the ideal location for the proposed training: The primary mentor will guide me in planning, organizing, and executing funded human research at the institution’s NIA-funded Alzheimer’s Disease Research Center. The team of mentors and collaborators includes experienced NIH-funded vision scientists who will provide training in advanced OCT techniques and Müller glial cell culture. Additional UC Davis training and analytic resources leveraged by this proposal include graduate- level coursework in vision science and the biology of neuroglia, the NIH-funded Clinical and Translational Science Center, and the NIH-funded Mutant Mouse Regional Resource Center.
项目摘要/摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Philip Bissig其他文献

David Philip Bissig的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Philip Bissig', 18)}}的其他基金

Manganese-Enhanced MRI Studies of Vision Loss with Aging
随年龄增长而丧失视力的锰增强 MRI 研究
  • 批准号:
    8519188
  • 财政年份:
    2010
  • 资助金额:
    $ 16.4万
  • 项目类别:
Manganese-Enhanced MRI Studies of Vision Loss with Aging
随年龄增长而丧失视力的锰增强 MRI 研究
  • 批准号:
    8002443
  • 财政年份:
    2010
  • 资助金额:
    $ 16.4万
  • 项目类别:
Manganese-Enhanced MRI Studies of Vision Loss with Aging
随年龄增长而丧失视力的锰增强 MRI 研究
  • 批准号:
    8132507
  • 财政年份:
    2010
  • 资助金额:
    $ 16.4万
  • 项目类别:
Manganese-Enhanced MRI Studies of Vision Loss with Aging
随年龄增长而丧失视力的锰增强 MRI 研究
  • 批准号:
    8313932
  • 财政年份:
    2010
  • 资助金额:
    $ 16.4万
  • 项目类别:

相似海外基金

Environmental copper exposure and its impact on microglial Abeta clearance
环境铜暴露及其对小胶质细胞 Abeta 清除的影响
  • 批准号:
    8757425
  • 财政年份:
    2014
  • 资助金额:
    $ 16.4万
  • 项目类别:
Development of Novel Therapies for AD Targeting Abeta Clearance
针对 Abeta 清除的 AD 新型疗法的开发
  • 批准号:
    8820188
  • 财政年份:
    2014
  • 资助金额:
    $ 16.4万
  • 项目类别:
Development of Novel Therapies for AD Targeting Abeta Clearance
针对 Abeta 清除的 AD 新型疗法的开发
  • 批准号:
    9040023
  • 财政年份:
    2014
  • 资助金额:
    $ 16.4万
  • 项目类别:
Environmental copper exposure and its impact on microglial Abeta clearance
环境铜暴露及其对小胶质细胞 Abeta 清除的影响
  • 批准号:
    8930156
  • 财政年份:
    2014
  • 资助金额:
    $ 16.4万
  • 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
  • 批准号:
    8897941
  • 财政年份:
    2013
  • 资助金额:
    $ 16.4万
  • 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
  • 批准号:
    8411069
  • 财政年份:
    2013
  • 资助金额:
    $ 16.4万
  • 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
  • 批准号:
    8713897
  • 财政年份:
    2013
  • 资助金额:
    $ 16.4万
  • 项目类别:
The role of human ApoE in soluble ABeta clearance through the LDLR in vivo
人 ApoE 在体内通过 LDLR 清除可溶性 Aβ 中的作用
  • 批准号:
    7752282
  • 财政年份:
    2009
  • 资助金额:
    $ 16.4万
  • 项目类别:
The role of human ApoE in soluble ABeta clearance through the LDLR in vivo
人 ApoE 在体内通过 LDLR 清除可溶性 Aβ 中的作用
  • 批准号:
    8090296
  • 财政年份:
    2009
  • 资助金额:
    $ 16.4万
  • 项目类别:
Development of therapeutics for dementia targeting Abeta clearance
开发针对 Abeta 清除的痴呆疗法
  • 批准号:
    20590697
  • 财政年份:
    2008
  • 资助金额:
    $ 16.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了